Biophytis is a clinical-stage biotechnology company focused on the development of innovative therapeutics to treat age-related diseases and functional decline. Founded in 2006 and headquartered in Paris, France, the company operates through its subsidiaries in Europe and the United States, leveraging a multidisciplinary approach that combines pharmacology, clinical research and regulatory expertise. Biophytis is dedicated to addressing unmet medical needs in the fields of muscle health and ophthalmology by advancing molecules with novel mechanisms of action through late-stage clinical development.
The company’s lead asset, BIO101 (sarconeos), is being evaluated as a treatment for sarcopenia—the progressive loss of muscle mass and strength associated with aging—as well as acute respiratory distress syndromes linked to viral infections. BIO101 acts on the Mas receptor, a component of the renin-angiotensin system, to promote muscle regeneration and reduce inflammation. In parallel, Biophytis is developing Macuneos (BIO201) for the treatment of dry age-related macular degeneration, aiming to slow retinal degeneration through neuroprotective and anti-oxidative mechanisms. Both programs are advancing under international clinical trials, with data readouts anticipated to inform regulatory filings.
Biophytis maintains operations in key pharmaceutical hubs, including research and development centers in Paris and a subsidiary in Boston, Massachusetts, to facilitate collaboration with North American academic institutions and contract research organizations. The company’s business model emphasizes forging strategic partnerships for co-development and licensing to expand its global reach and accelerate commercialization pathways. Biophytis also engages with patient advocacy groups and scientific consortia to align its development programs with community needs and regulatory expectations.
Leadership at Biophytis comprises seasoned executives and experts in biotechnology and life sciences. Xavier Passot, Chief Executive Officer, brings over two decades of experience in clinical development and corporate strategy. The company’s board and scientific advisory committees include specialists in gerontology, ophthalmology and pharmacology, ensuring robust oversight of study design and regulatory strategy. As Biophytis progresses toward pivotal trial milestones, it remains focused on delivering therapies that can improve quality of life for aging populations worldwide.
AI Generated. May Contain Errors.
Free BPTSY Stock Alerts